

<b>General information about company</b>	
Scrip code	542650
NSE Symbol	METROPOLIS
MSEI Symbol	NOTLISTED
ISIN*	INE112L01020
Name of company	METROPOLIS HEALTHCARE LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2019
Date of end of financial year	31-03-2020
Date of board meeting when results were approved	06-02-2020
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-01-2020
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Pathology
Start date and time of board meeting	06-02-2020 14:00
End date and time of board meeting	06-02-2020 17:30
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	22285.38	64943.09
	Other income	218.95	549.54
	<b>Total income</b>	<b>22504.33</b>	<b>65492.63</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	5232.36	15319.2
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	4841.33	14523.57
(e)	Finance costs	239.58	606.73
(f)	Depreciation, depletion and amortisation expense	1055.91	2812.3
<b>(f)</b>	<b>Other Expenses</b>		
1	Laboratory testing charges	123.19	429.38
2	Other Expenses	5732.07	16528.46
10			
	<b>Total other expenses</b>	<b>5855.26</b>	<b>16957.84</b>
	<b>Total expenses</b>	<b>17224.44</b>	<b>50219.64</b>

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	5279.89	15272.99
4	Exceptional items	0	-738.46
<b>5</b>	<b>Total profit before tax</b>	5279.89	14534.53
<b>7</b>	<b>Tax expense</b>		
8	Current tax	1173.52	3371.84
9	Deferred tax	-95.02	-43.19
<b>10</b>	<b>Total tax expenses</b>	1078.5	3328.65
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	4201.39	11205.88
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	4201.39	11205.88

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
1	Items that will not be reclassified subsequently to profit and loss (net of tax)	-8.26	-173.51
	<b>Total Amount of items that will not be reclassified to profit and loss</b>	-8.26	-173.51
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	0	0
<b>3 Amount of items that will be reclassified to profit and loss</b>			
1	Items that will not be reclassified subsequently to profit and loss (net of tax)	8.11	0.56
	<b>Total Amount of items that will be reclassified to profit and loss</b>	8.11	0.56
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0	0
5	<b>Total Other comprehensive income</b>	-0.15	-172.95

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	4201.24	11032.93
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent	4207.22	11183.27
	Total profit or loss, attributable to non-controlling interests	-5.83	22.61
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	4207.08	11010.65
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-5.84	22.28
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	1003.57	1003.57
	Face value of equity share capital	2	2
<b>27</b>	<b>Details of debt securities</b>		
<b>28</b>	Reserves excluding revaluation reserve		
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	8.38	22.29
	Diluted earnings (loss) per share from continuing operations	8.37	22.24
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	8.38	22.29
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	8.37	22.24
<b>30</b>	Debt equity ratio		
<b>31</b>	Debt service coverage ratio		
<b>32</b>	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

### Textual Information(1)

#### Notes

1. These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The above unaudited results were reviewed by the Audit Committee at their meeting held on 6 February 2020 and thereafter approved by the Board of Directors at their meeting held on 6 February 2020. The statutory auditors have expressed an unmodified review opinion.
3. Metropolis Healthcare Limited (the 'Company' or the 'Parent'), and its subsidiaries (referred to collectively as the 'Group') and its joint venture are primarily involved in providing pathology and related healthcare services.
4. The Group has adopted Ind AS 116, effective annual reporting period beginning 01 April 2019 and applied the standard to its leases, retrospectively, with the cumulative effect of initially applying the Standard, recognised on the date of initial application (01 April 2019). Accordingly, the Group has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on 01 April 2019. The Group has adopted Ind AS 116 using the cumulative effect method for transitioning.
5. Exceptional items in the consolidated financial results for the nine months ended 31 December 2019 includes: -
  - a) provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 Lakhs and;
  - b) provision for Rs.350.00 Lakhs on account of certain old unreconciled balances.
6. Disclosure of segment –wise information is not applicable, as pathology services is the Group's only business segment.
7. The Company completed an Initial Public Offer through an offer for sale by the selling shareholders of 1,36,85,095 equity shares of Rs.2 each at price of Rs. 880. The equity shares of the Company got listed on the BSE Limited and National Stock Exchange of India Limited on 15 April 2019. Expenses related to the offer are being borne by selling shareholders.
8. The Consolidated financial results for the quarter ended 31 December 2018 and nine months ended 31 December 2018 were not subjected to limited review by the Statutory auditors and are as prepared by the Parents' management.
9. The Company has through its wholly owned subsidiary "Desai Metropolis Health Services Private Limited", has acquired 4 (four) Laboratories from: (i) Doctor's Clinical Laboratory (partnership firm), (ii) Iyer Pathology Laboratory (sole proprietary), (iii) Nagar Pathology Laboratory (sole proprietary) and (iv) Yash Clinical Laboratory (sole proprietary), for providing diagnostic and pathological testing services in Surat, Gujarat as on 30 September 2019 for purchase consideration of Rs. 1,800 lakhs payable in 3 tranches starting from 30 September 2019.
10. The Company is in process of acquiring 51% shareholding of Shraddha Diagnostic Centre (I) Private Limited for providing diagnostic and pathological testing services in Ahmedabad, Gujarat as approved in Board Meeting held on 15th January 2020 to strengthen the presence of the Company in the state of Gujarat for purchase consideration of Rs. 936.30 lakhs. The same is expected to be closed within three months from the date of approval of the Board.
11. The Board of Directors of the Company have approved the interim dividend of Rs. 8 per equity share (Face value of Rs. 2 each) at the meeting held on 06 February 2020.
12. The Company and its Indian subsidiary companies have elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company and certain subsidiary companies have recognised Provision of Income Tax for the nine months ended 31 December 2019 and re-measured its Deferred Tax basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the quarter ended 30 September 2019 and nine months period ended

31 December 2019.

13. The results of the Company are available for investors at [www.metropolisindia.com](http://www.metropolisindia.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

<b>Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results</b>		
<b>Particulars</b>	<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
Date of start of reporting period	01-10-2019	01-04-2019
Date of end of reporting period	31-12-2019	31-12-2019
Whether accounts are audited or unaudited		Unaudited
Nature of report standalone or consolidated	Consolidated	Consolidated
<b>1 Segment Revenue (Income)</b>		
<b>(net sale/income from each segment should be disclosed)</b>		
<b>Total Segment Revenue</b>		
<b>Less: Inter segment revenue</b>		
<b>Revenue from operations</b>		
<b>2 Segment Result</b>		
<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
<b>Total Profit before tax</b>		
<b>i. Finance cost</b>		
<b>ii. Other Unallocable Expenditure net off Unallocable income</b>		
<b>Profit before tax</b>		
<b>3 (Segment Asset - Segment Liabilities)</b>		
<b>Segment Asset</b>		
<b>Total Segment Asset</b>		
<b>Un-allocable Assets</b>		
<b>Net Segment Asset</b>		
<b>4 Segment Liabilities</b>		
<b>Segment Liabilities</b>		
<b>Total Segment Liabilities</b>		
<b>Un-allocable Liabilities</b>		
<b>Net Segment Liabilities</b>		
<b>Disclosure of notes on segments</b>		



